Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01318954 · ClinicalTrials.gov registry record

The Effect of Allergen Immunotherapy on Exhaled Nitric Oxide in Adult Patients With Asthma and Allergic Rhinitis

A clinical trial, sponsored by Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C..

Completed
Registry status
17
Enrollment target

NCT01318954: Completed study, sponsored by Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C..

NCT01318954 is a clinical trial that has completed, run by Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01318954 has completed, sponsored by Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C..

COMPLETED
Registry status
17 participants
Enrollment target

Study Summary

This study will evaluate whether exhaled nitric oxide levels are affected by allergen immunotherapy ("allergy shots"). The investigators' hypothesis is that successful allergen immunotherapy may be accompanied by decreased exhaled nitric oxide levels.

Interventions

  • BIOLOGICAL Allergen immunotherapy

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2008-01
Est. Completion 2011-06

What the Registry Record Tells You About NCT01318954

The ClinicalTrials.gov registry entry for NCT01318954 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C., which has 5 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Allergen immunotherapy is the first listed.

NCT01318954 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01318954 about?

NCT01318954 is a clinical study titled "The Effect of Allergen Immunotherapy on Exhaled Nitric Oxide in Adult Patients With Asthma and Allergic Rhinitis". This study will evaluate whether exhaled nitric oxide levels are affected by allergen immunotherapy ("allergy shots"). The investigators' hypothesis is that successful allergen immunotherapy may be accompanied by decreased exhaled nitric oxide levels.

What is the current status of trial NCT01318954?

This trial is currently completed. The enrollment target is 17 participants. The study started on 2008-01. Estimated completion is 2011-06.

What interventions are being tested in trial NCT01318954?

The interventions under investigation include: Allergen immunotherapy (BIOLOGICAL).

Who is sponsoring clinical trial NCT01318954?

This trial is sponsored by Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C., which has 5 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.